proteinprotein
interact
ppi
involv
vast
major
biolog
process
fletcher
hamilton
fri
ryan
matthew
toogood
zinzalla
thurston
nearli
everi
import
pathway
health
diseas
includ
critic
influenc
ppi
fri
context
specif
control
modul
inhibit
ppi
provid
promis
avenu
ration
drug
design
reveal
recent
progress
design
inhibitori
antibodi
peptid
small
molecul
berg
che
brook
marshal
fri
pagliaro
et
al
robinson
sillerud
larson
veselovski
archakov
cell
surfac
receptor
integr
membran
protein
translat
extracellular
inform
intracellular
signal
sequenc
physiolog
cell
respons
complex
fundament
process
call
transmembran
signal
transduct
process
play
crucial
role
health
diseas
kadmiel
cidlowski
rudd
sabro
et
al
sigalov
make
therapeut
control
ppi
involv
process
fundament
clinic
import
howev
recent
lack
mechanist
understand
ppi
actual
take
place
transmembran
signal
transduct
significantli
imped
progress
fundament
studi
biolog
life
scienc
also
molecular
targetdriven
drug
discoveri
result
lack
understand
wide
use
therapeut
strategi
receptor
modul
attempt
prevent
bind
receptor
cognat
ligand
use
clinic
relev
antibodi
hansel
kropshof
singer
mitchel
georg
solubl
receptor
domain
bouchon
facchetti
weigand
colonna
molloy
sewel
jakobsen
howev
larg
protein
entiti
possess
sever
disadvantag
includ
long
costli
develop
process
low
activ
per
mass
manufactur
difficulti
unintend
immun
respons
side
effect
low
organ
tissu
penetr
lack
oral
bioavail
hansel
et
al
integr
membran
protein
cell
surfac
receptor
consist
three
domain
extracellular
ligandbind
domain
function
detect
bind
extern
stimuli
transmembran
domain
function
anchor
cell
membran
mediat
signal
transduct
cytoplasm
signal
domain
initi
intracellular
signal
transduct
cascad
depend
whether
extracellular
intracellular
domain
locat
separ
protein
chain
unrel
function
divers
cell
receptor
divid
two
main
structur
famili
singlechain
multichain
receptor
sr
mr
respect
fig
keegan
paul
sigalov
sigalov
mr
commonli
repres
immun
receptor
often
refer
multichain
immun
recognit
receptor
mirr
keegan
paul
sigalov
signatur
featur
mirr
presenc
one
copi
immunoreceptor
tyrosinebas
activ
motif
itam
region
reth
yxxm
motif
wu
cherwinski
spi
phillip
lanier
cytoplasm
signal
domain
upon
receptor
trigger
tyrosin
residu
itamyxxm
region
phosphoryl
earli
obligatori
event
signal
cascad
gener
platform
receptormedi
transmembran
signal
transduct
signal
chain
homooligomer
school
platform
sigalov
sigalov
sigalov
sigalov
sigalov
sigalov
sigalov
uncov
first
time
major
mechan
coupl
recognit
signal
function
base
unusu
biophys
phenomenonth
abil
intrins
disord
cytoplasm
domain
mirr
signal
subunit
form
specif
homodim
higher
homooligom
sigalov
aivazian
stern
sigalov
zhuravleva
orekhov
platform
origin
suggest
mirr
sigalov
thena
gener
platform
transmembran
signal
mediat
mirr
sr
sigalov
sigalov
conceptu
school
platform
suggest
similar
architectur
receptor
dictat
similar
mechan
receptor
trigger
mechanist
accord
platform
multival
ligand
bind
outsid
cell
induc
tune
receptor
oligomer
cluster
translat
across
membran
format
compet
signal
homooligom
cytoplasm
milieua
forc
drive
transmembran
signal
necessari
suffici
trigger
receptor
activ
fig
provid
similar
target
reveal
level
specif
ppisbiochem
process
influenc
control
therapeut
purpos
sigalov
sigalov
sigalov
sigalov
red
intracellular
signal
domain
green
signal
sequenc
orang
rectangl
locat
protein
chain
signal
chain
homooligomer
school
model
sr
signal
model
propos
receptor
homooligomer
cytoplasm
milieu
play
central
role
trigger
sr
ligandinduc
sr
cluster
reorient
andor
receptor
reorient
preexist
sr
cluster
result
sr
oligomer
mediat
transmembran
interact
charg
residu
oligom
receptor
suffici
proxim
adopt
correct
interreceptor
rel
orient
geometri
promot
homointeract
cytoplasm
domain
format
compet
signal
oligom
result
gener
activ
signal
receptor
tyrosin
kinas
mean
transautophosphoryl
tyr
residu
cytoplasm
signal
sequenc
thu
trigger
downstream
signal
pathway
proteinprotein
interact
shown
solid
black
arrow
b
multichain
immun
school
platform
consid
homooligomer
cytoplasm
signal
domain
cell
surfac
receptor
sr
mirr
drive
forc
transmembran
signal
suggest
bring
domain
correct
orient
close
enough
proxim
one
promot
homotyp
ppi
obligatori
step
trigger
receptor
sigalov
sigalov
defin
process
ligandinduc
receptor
trigger
activ
outcom
interplay
three
major
drive
forc
extracellular
ppi
receptor
cognat
ligand
inter
sr
intrareceptor
mirr
ppi
cell
membran
interreceptor
homotyp
ppi
cytoplasm
milieu
interestingli
transmembran
signal
mediat
receptor
tyrosin
kinas
rtk
member
sr
famili
weak
dimer
propens
rtk
transmembran
domain
allow
tight
control
ratio
receptor
monom
dimer
finger
escher
schneider
li
hristova
mirrmedi
signal
three
major
ppi
indic
earlier
character
micromolar
affin
rel
rapid
kinet
bormann
engelman
davi
et
al
finger
et
al
sigalov
et
al
conjug
wellbalanc
system
ppi
involv
receptor
trigger
explain
molecular
mechan
underli
abil
mirr
transduc
divers
recognit
recognit
receptor
mirr
extracellular
recognit
domain
intracellular
itamcontain
signal
domain
locat
separ
subunit
bound
togeth
noncoval
intramembran
interact
solid
arrow
itam
color
orang
signal
chain
homooligomer
school
model
mirr
signal
model
propos
homooligomer
signal
subunit
cytoplasm
milieu
play
key
role
trigger
mirr
ligandinduc
mirr
cluster
reorient
andor
receptor
reorient
preexist
mirr
cluster
lead
format
dimericoligomer
intermedi
intermedi
receptor
suffici
proxim
adopt
correct
rel
orient
geometri
promot
transhomointeract
cytoplasm
domain
signal
subunit
result
format
compet
signal
oligom
oligom
protein
tyrosin
kinas
phosphoryl
itam
tyrosin
residu
lead
gener
activ
signal
dissoci
signal
oligom
intern
engag
mirr
ligandbind
subunit
circular
arrow
indic
ligandinduc
receptor
reorient
interchain
interact
dimer
intermedi
shown
dot
black
arrow
reflect
transit
state
curv
line
depict
disord
cytoplasm
domain
mirr
signal
subunit
phosphat
group
shown
purpl
circl
abbrevi
itam
immunoreceptor
tyrosinebas
activ
motif
discrimin
inform
across
cell
membran
translat
differ
signal
cascad
thu
trigger
differ
intracellular
pathway
provid
differ
cell
respons
immun
defens
system
ppi
explain
mechanist
immun
cell
high
specif
select
sensit
recognit
discrimin
differ
antigen
ligand
recognit
discrimin
result
differ
function
outcom
contrast
wellestablish
strategi
target
interact
receptor
ligand
order
modul
receptor
signal
school
strategi
target
ppi
involv
receptormedi
transmembran
signal
transductionintramembran
cytoplasm
homotyp
ppi
freedom
bind
signal
strategi
allow
effect
select
therapeut
target
use
small
molecul
inhibitor
modulatori
peptid
peptidomimet
accord
school
platform
sigalov
sigalov
upon
bind
multival
ligand
intramembran
ppi
sr
mediat
dimer
oligomer
sr
bring
receptor
close
proxim
correct
interreceptor
geometri
promot
cytoplasm
homotyp
ppi
thu
trigger
receptor
fig
interestingli
rtk
sr
member
tumor
necrosi
factor
tnf
receptor
superfamili
chan
chan
siegel
lenardo
exist
preassembl
dimer
oligom
surfac
rest
cell
scenario
platform
suggest
bind
multival
ligand
lead
reorient
receptor
dimer
oligom
adopt
geometri
compet
promot
dimer
oligomer
cytoplasm
signal
domain
trigger
receptor
fig
inde
rtkmediat
signal
multival
ligand
bind
result
conform
chang
receptor
extracellular
domain
lead
rotat
whole
receptor
jiang
hunter
moriki
maruyama
maruyama
trigger
neu
rtk
occur
specif
transmembran
dimer
interfac
rotat
lead
period
oscil
kinas
activ
bell
et
al
confirm
necess
correct
interreceptor
orient
receptor
dimer
oligom
form
upon
bind
multival
ligand
addit
rotat
rtk
domain
respect
transmembran
domain
insert
residu
ctermin
transmembran
flank
region
restor
rtk
activ
furthermor
upon
bind
epiderm
growth
factor
receptor
egfr
cognat
ligand
egfr
extracellular
domain
rotat
rotat
transmit
receptor
transmembran
domain
moriki
et
al
interreceptor
orient
receptor
dimer
play
critic
role
erythropoietin
receptormedi
transmembran
signal
livnah
et
al
sy
et
al
suggest
tight
coupl
extracellular
domain
orient
cytoplasm
signal
event
furthermor
signal
transduct
via
interleukin
il
requir
homodimer
also
correct
rel
orient
cytoplasm
domain
ligandspecif
receptor
dimer
suggest
subtl
chang
orient
receptor
chain
rel
might
result
differ
respons
greiser
stross
heinrich
behrmann
hermann
dimer
cytokin
receptor
monoclon
antibodi
case
enough
induc
signal
transduct
autissi
et
al
format
homooligom
fa
cytoplasm
tail
play
import
role
receptor
trigger
siegel
et
al
similarli
cytoplasm
domainmedi
dimer
tolllik
necessari
trigger
activ
signal
cascad
lee
dunzendorf
tobia
thu
studi
sr
strongli
support
gener
school
platform
concept
demonstr
ligandinduc
receptor
dimer
translat
protein
dimer
cell
membran
milieu
receptor
dimer
intramembran
interfac
contain
critic
structur
inform
posit
receptor
cytoplasm
signal
domain
way
compet
oligomer
receptor
trigger
fig
transmembran
signal
mediat
mirr
roughli
divid
four
stage
recognit
bind
receptor
multival
cognat
ligand
outsid
cell
transmembran
transduct
inform
cytoplasm
milieu
phosphoryl
itam
yxxm
tyrosin
residu
protein
tyrosin
kinas
follow
activ
specif
intracellular
signal
cascad
activ
gene
nucleu
molecular
mechan
underli
stage
understood
signific
detail
mechan
mirr
transduc
recognit
discrimin
inform
via
receptor
transmembran
juxtamembran
region
intracellular
biochem
event
stage
longstand
mysteri
also
clear
put
mechan
could
explain
intrigu
abil
immun
cell
discern
differenti
respond
slightli
differ
ligand
immun
defens
ultim
specif
ppi
involv
process
remain
larg
unknown
prevent
develop
novel
therapeut
approach
uncov
crucial
physiolog
role
homotyp
interact
intrins
disord
cytoplasm
domain
mirr
signal
subunit
sigalov
sigalov
et
al
sigalov
et
al
biophys
uniqu
phenomenon
still
remain
matter
debat
whether
exist
nours
mittag
sigalov
uverski
dunker
school
model
suggest
format
compet
mirr
signal
subunit
oligom
necessari
suffici
trigger
receptor
induc
downstream
signal
cascad
fig
sigalov
sigalov
sigalov
sigalov
sigalov
consist
structur
hypothesi
crossphosphoryl
ortega
pribluda
pribluda
metzger
assum
kinas
respons
catalyz
itam
tyr
residu
phosphoryl
exist
associ
receptor
steric
reason
kinas
phosphoryl
tyrosin
residu
itamcontain
signal
chain
receptor
complex
contrast
mirr
dimer
oligom
form
upon
bind
multival
cognat
ligand
kinas
phosphoryl
tyrosin
distinct
receptor
complex
crossphosphoryl
transphosphoryl
thu
trigger
receptor
ortega
unstimul
rest
cell
intramembran
ppi
transmembran
helic
recognit
signal
mirr
subunit
maintain
receptor
integr
determin
rel
posit
subunit
receptor
complex
angl
distanc
etc
thu
dictat
overal
geometri
topolog
mirr
biassoni
et
al
call
pyrdol
wiedmann
wucherpfennig
daeron
defranco
et
al
kim
et
al
klesneytait
turnbul
colonna
moroi
jung
sigalov
sigalov
sigalov
school
platform
suggest
mirr
engag
multival
ligand
antimirr
antibodi
eg
antibodi
cell
receptor
chain
tcr
antibodi
b
cell
receptor
lead
receptor
dimer
oligomer
coupl
multistep
structur
reorgan
aim
promot
homotyp
ppi
mirr
signal
subunit
cytoplasm
milieu
trigger
receptor
initi
downstream
signal
cascad
fig
accord
school
model
suffici
close
interreceptor
proxim
correct
rel
orient
mirr
dimer
oligom
well
long
enough
durat
mirrligand
interact
suffici
lifetim
individu
receptor
mirr
cluster
play
import
role
product
mirr
trigger
strongli
support
grow
bodi
evid
carreno
gonzalez
kalergi
holler
lim
cho
rund
kranz
holowka
sil
torigo
baird
kiessl
gestwicki
strong
klemm
schreiber
crabtre
metzger
miura
takahashi
jung
moroi
ortega
schweitzerstenn
pecht
posner
et
al
puffer
pontrello
hollenbeck
kink
kiessl
radaev
sun
reth
wienand
schweitzerstenn
tamir
pecht
tamir
cambier
yamasaki
ishikawa
kohno
saito
mirr
tcr
major
platelet
collagen
receptor
glycoprotein
vi
gpvi
exist
preassembl
oligom
surfac
rest
cell
berlanga
et
al
jung
tsuji
moroi
schamel
et
al
scenario
similarli
sr
school
model
suggest
reorient
mirr
dimer
oligom
adopt
geometri
compet
promot
homotyp
ppi
cytoplasm
signal
domain
trigger
receptor
immun
defens
school
mechan
suggest
divers
immun
cell
respons
larg
provid
combinatori
natur
mirrmedi
signal
specif
signal
diversif
may
achiev
differ
pattern
mirr
signal
subunit
oligomer
sigalov
sigalov
sigalov
combin
distinct
activ
signal
provid
differ
mirr
signal
modul
jensen
et
al
pike
baig
ratcliff
pitcher
van
oer
sanchezmejorada
rosal
andor
differ
itam
locat
signal
modul
eg
chain
chae
et
al
thu
accord
model
divers
cell
function
outcom
respons
stimul
differ
ligand
increas
number
differ
signal
subunit
mirr
complex
structur
consider
transmembran
signal
mediat
varieti
function
unrel
receptor
express
variou
cell
lead
us
import
observ
recognit
signal
function
combin
one
protein
chain
sr
separ
differ
protein
chain
mirr
fig
anoth
observ
extracellular
ligand
recognit
transmembran
cytoplasm
signal
domain
sr
well
structur
sigalov
sigalov
sigalov
cytoplasm
domain
mirr
signal
subunit
intrins
disord
ie
domain
lack
welldefin
order
structur
physiolog
condit
vitro
contrast
wellstructur
mirr
extracellular
ligand
recognit
transmembran
domain
sigalov
sigalov
sigalov
sigalov
et
al
sigalov
et
al
sigalov
aivazian
uverski
stern
ultim
observ
rais
two
intrigu
question
sigalov
sigalov
first
natur
separ
recognit
signal
function
mirr
therebi
increas
risk
malfunct
potenti
attack
pathogen
second
natur
select
protein
disord
mirr
translat
recognit
distinct
ligand
appropri
activ
signal
would
induc
distinct
specif
function
outcom
fig
answer
first
question
one
suggest
modular
assembl
mirr
bring
multipl
benefit
import
capabl
diversifi
vari
signal
transduct
sigalov
sigalov
sigalov
sigalov
ultim
provid
mechanist
basi
fig
evolutionari
molecular
aspect
transmembran
signal
transduct
mediat
singleand
multichain
cell
surfac
receptor
imag
creat
use
pymol
wwwpymolorg
protein
data
bank
entri
egfr
extraand
intracellular
juxtamembran
kinas
domain
respect
shown
exampl
structur
singlechain
receptor
entri
extracellular
domain
shown
exampl
structur
multichain
receptor
recognit
subunit
illustr
purpos
cytoplasm
domain
multichain
receptorassoci
signal
subunit
shown
monom
use
arbitrari
ideal
structur
element
repres
ensembl
unfold
conform
idr
immunoreceptor
tyrosinebas
activ
motif
itam
multichain
receptor
depict
green
intramembran
interact
recognit
signal
subunit
multichain
receptor
shown
gray
arrow
abbrevi
egfr
epiderm
growth
factor
receptor
fc
receptor
iga
divers
variabl
immun
respons
accord
charl
darwin
divers
variabl
core
evolutionari
process
darwin
one
conclud
natur
take
risk
associ
separ
function
mirr
exchang
high
potenti
evolut
signal
transduct
fig
context
immun
signal
great
import
develop
evolut
immun
defens
protein
disord
contribut
divers
variabl
signal
transduct
without
compromis
effici
specif
signal
sigalov
sigalov
sigalov
sigalov
sigalov
thu
evolutionari
development
benefit
immun
signalingrel
protein
disord
outweigh
attend
disadvantag
larg
compens
increas
host
defens
exist
two
type
immun
receptor
innat
receptor
germ
lineencod
receptor
detect
limit
set
conserv
antigen
adapt
receptor
somat
gener
antigen
receptor
b
cell
tcr
bcr
respect
tabl
evolutionari
standpoint
adapt
immun
respons
evolv
long
innat
mechan
selfdefens
provid
signific
ad
valu
promot
surviv
cooper
alder
kimbrel
beutler
litman
cooper
structur
adapt
receptor
belong
mirr
famili
two
bcr
four
tcr
signal
chain
fig
contrast
innat
receptor
belong
sr
famili
eg
tlr
repres
mirr
contain
one
signal
chain
eg
trigger
receptor
express
myeloid
cell
trem
natur
killer
cell
receptor
nk
receptor
fig
importantli
function
itam
modul
includ
locat
differ
jensen
et
al
pike
et
al
pitcher
van
oer
sanchezmejorada
rosal
sigalov
sigalov
sigalov
sigalov
sigalov
eg
three
differ
itam
chain
chae
et
al
signal
chain
locat
chain
rather
distinct
instead
redund
provid
molecular
explan
significantli
higher
divers
variabl
adapt
respons
compar
innat
respons
interestingli
follow
logic
one
conclud
extent
divers
variabl
signal
intermedi
innat
eg
tlr
adapt
receptor
fig
inde
consist
idea
nk
cell
repres
evolutionari
bridg
innat
adapt
immun
sun
lanier
biochem
process
influenc
control
archakov
et
al
arkin
well
berg
fletcher
hamilton
pagliaro
et
al
intramembran
ppi
mirr
recognit
signal
subunit
well
homotyp
interact
cytoplasm
domain
mirr
signal
subunit
repres
potenti
point
attack
pathogen
order
modul
mirrmedi
signal
thu
modul
immun
respons
sigalov
sigalov
exampl
virus
billionyearslong
struggl
exist
order
establish
success
infect
replic
persist
host
evolv
numer
strategi
counter
evad
host
antivir
immun
respons
well
exploit
product
viral
replic
sever
differ
virus
human
immunodefici
viru
hiv
cytomegaloviru
cmv
sever
acut
respiratori
syndrom
coronaviru
sarscov
human
herpesviru
pathogen
human
uniformli
target
member
mirr
famili
includ
innat
adapt
receptor
intriguingli
virus
use
either
modular
assembl
mirr
disrupt
receptormedi
signal
cytoplasm
protein
disord
mirr
surprisingli
augment
cell
activ
requir
selfpreserv
cohen
cohen
antonovski
cohen
shai
shen
sigalov
sigalov
sigalov
sigalov
sigalov
exampl
coevolut
virus
host
confirm
evolut
develop
without
risk
although
avoid
risk
turn
lemon
lemonad
learn
natur
effici
target
immun
system
therapeut
purpos
kim
sigalov
shen
sigalov
sigalov
illustr
next
section
exampl
intramembran
ppi
therapeut
target
although
grow
line
experiment
evid
indic
target
intramembran
ppi
inhibit
modul
srmediat
cell
activ
might
repres
promis
therapeut
approach
bennasroun
et
al
bennasroun
et
al
hebert
et
al
sigalov
smith
et
al
tarasova
rice
michejda
work
focu
therapeut
intramembran
ppi
use
short
synthet
peptid
school
peptid
order
inhibit
mirrmedi
transmembran
signal
therapeut
purpos
importantli
receptorspecif
school
peptid
employ
molecular
mechan
receptor
inhibit
depend
upon
bind
receptor
cognat
ligand
especi
import
situat
ligand
still
unknown
exampl
receptor
despit
recent
evid
peptidoglycan
pgn
recognit
protein
may
potenti
act
ligand
read
et
al
actual
natur
ligand
still
yet
well
understood
imped
develop
clinic
relev
inhibitor
receptor
function
potent
amplifi
inflamm
mediat
product
proinflammatori
cytokin
bouchon
et
al
murakami
et
al
schenk
bouchon
seibold
mueller
importantli
activ
preferenti
induc
express
function
macrophag
colonystimul
factor
mcsf
also
known
dower
elli
saraf
jelinski
lin
contrast
cytokin
blocker
blockad
blunt
excess
inflamm
preserv
capac
microbi
control
weber
et
al
collect
find
implic
promis
therapeut
target
varieti
inflammationassoci
diseas
bosco
raggi
varesio
ford
mcvicar
tammaro
et
al
lung
cancer
lead
caus
cancer
death
worldwid
two
type
cancernonsmal
cell
lung
cancer
nsclc
small
cell
lung
cancer
despit
advanc
made
chemotherapi
felip
santarpia
rosel
nsclc
kill
million
peopl
annual
worldwid
surviv
rate
patient
nsclc
jemal
et
al
similar
solid
tumor
infiltr
nsclc
contain
tumorassoci
macrophag
tam
solina
germano
mantovani
allavena
secret
varieti
growth
factor
cytokin
chemokin
enzym
tam
regul
tumor
growth
angiogenesi
invas
metastasi
shih
yuan
chen
yang
high
tam
content
correl
promot
tumor
growth
metastasi
solina
et
al
associ
poor
prognosi
nsclc
welsh
et
al
tam
recruit
activ
growth
differenti
regul
mcsf
elgert
alleva
mullin
increas
pretreat
serum
mcsf
level
signific
independ
predictor
poor
surviv
patient
nsclc
kaminska
et
al
patient
nsclc
express
tam
associ
cancer
recurr
poor
surviv
patient
low
express
surviv
rate
compar
less
patient
high
express
ho
et
al
suggest
inhibit
pathway
may
promis
target
develop
target
anticanc
therapi
consid
unknown
natur
ligand
recent
studi
sigalov
use
school
platform
design
novel
ligandindepend
inhibitori
peptid
sequenc
demonstr
peptid
specif
block
transmembran
signal
vitro
vivo
util
two
human
nsclc
xenograft
nude
mous
model
demonstr
first
time
blockad
function
use
substanti
decreas
cytokin
product
vitro
significantli
delay
tumor
growth
vivo
also
show
school
peptid
inhibitor
formul
selfassembl
macrophagespecif
lipopeptid
lipoprotein
complex
mimic
human
high
densiti
lipoprotein
hdl
peptid
halflif
extens
target
deliveri
sigalov
incorpor
significantli
increas
therapeut
efficaci
sigalov
pancreat
cancer
pc
pancreat
ductal
adenocarcinoma
fourth
lead
caus
cancerrel
mortal
across
world
poor
clinic
outcom
hariharan
sai
kocher
current
treatment
pc
margin
prolong
surviv
reliev
symptom
patient
pc
schneider
sivek
eckel
schmid
signific
progress
field
target
therapi
pc
walker
ko
despit
tremend
effort
surviv
rate
remain
less
lung
cancer
mani
solid
tumor
pc
character
mark
infiltr
macrophag
stromal
compart
shih
et
al
solina
et
al
patient
pc
macrophag
infiltr
begin
preinvas
stage
diseas
increas
progress
clark
et
al
number
tam
significantli
higher
patient
metastas
gardian
janczewska
olszewski
durlik
presenc
tam
pc
stroma
correl
increas
angiogenesi
esposito
et
al
known
predictor
poor
prognosi
kuwahara
et
al
similar
nsclc
high
pretreat
serum
mcsf
strong
independ
predictor
poor
surviv
pc
patient
groblewska
et
al
interestingli
mcsf
blockad
suppress
tumor
angiogenesi
lymphangiogenesi
kubota
et
al
also
upregul
cell
checkpoint
molecul
includ
program
cell
death
protein
cytotox
lymphocyt
therebi
overcom
limit
antagonist
achiev
regress
even
wellestablish
tumor
zhu
et
al
importantli
continu
mcsf
inhibit
affect
patholog
angiogenesi
healthi
vascular
lymphat
system
outsid
tumor
kubota
et
al
contrast
blockad
vascular
endotheli
growth
factor
vegf
interrupt
mcsf
inhibit
promot
rapid
vascular
regrowth
kubota
et
al
activ
known
enhanc
releas
cytokin
increas
patient
pc
tjomsland
et
al
yako
kruger
smith
brand
play
vital
role
creat
sustain
inflamm
tumor
favor
microenviron
thu
affect
patient
surviv
includ
monocyt
chemoattract
mcsf
lagler
et
al
schenk
et
al
sigalov
collect
find
suggest
therapi
target
intratumor
inflamm
angiogenesi
vascular
repres
promis
strategi
treat
pc
recent
test
therapeut
potenti
inhibitori
peptid
sequenc
three
human
pc
xenograft
mous
model
zu
shen
alexand
b
sigalov
unpublish
administr
school
peptid
result
strong
antitumor
effect
achiev
optimaltreatedcontrol
tc
valu
depend
xenograft
formul
use
persist
even
treatment
halt
effect
correl
significantli
increas
surviv
reduc
angiogenesi
suppress
tam
infiltr
peptid
well
toler
deploy
either
free
form
formul
hdlmimick
macrophagetarget
lipopeptid
complex
blockad
significantli
reduc
serum
level
mcsf
vegf
suggest
mcsfdepend
inhibitori
effect
angiogenesi
taken
togeth
previou
studi
sigalov
data
suggest
school
peptid
inhibitor
cancer
type
independ
therapeut
benefici
antitumor
activ
potenti
use
standalon
therapi
compon
combin
therapi
pc
nsclc
solid
tumor
autoimmun
diseas
fascin
poorli
understood
group
diseas
character
specif
adapt
immun
respons
mount
selfantigen
davidson
diamond
result
effector
pathway
immun
caus
chronic
inflammatori
injuri
tissu
may
often
prove
lethal
exampl
rheumatoid
arthriti
ra
system
lupu
erythematosu
inflammatori
bowel
diseas
multipl
sclerosi
atop
dermat
ad
disord
cell
macrophag
two
main
subtyp
immun
cell
known
implic
mediat
mani
aspect
autoimmun
inflamm
ra
chronic
system
inflammatori
disord
caus
chronic
inflamm
joint
affect
world
popul
women
affect
three
time
often
men
econom
burden
creat
ra
enorm
annual
direct
indirect
cost
per
patient
respect
explain
high
demand
new
therapi
kukar
petryna
efthimi
typic
new
approach
ra
involv
use
monoclon
antibodi
peptid
antigen
mimet
cell
vaccin
infusioninject
antiinflammatori
cytokin
cytokin
inhibitor
kukar
et
al
kurosaka
ali
byth
manolio
howev
current
ra
treatment
includ
tnf
blocker
humira
multipl
shortcom
includ
high
level
seriou
side
effect
insuffici
efficaci
thu
highlight
need
new
improv
treatment
pathogenesi
ra
suggest
key
role
aberr
pathway
cell
activ
initi
andor
perpetu
diseas
cope
schulzekoop
aring
sakaguchi
benham
cope
thoma
make
inhibit
pathway
involv
cell
activ
includ
tcrmediat
cell
activ
promis
therapeut
strategi
novel
ra
therapi
lorenz
lee
ad
inflammatori
skin
autoimmun
diseas
character
impair
epiderm
barrier
function
cutan
inflamm
preval
ad
steadili
increas
past
decad
ad
affect
adult
children
diseas
onset
age
year
novak
novel
therapeut
approach
requir
treatment
ad
limit
symptomat
therapi
activ
skinselect
home
peripher
blood
cell
effector
function
skin
involv
pathogenesi
ad
akdi
akdi
trautmann
blaser
numer
studi
point
role
activ
cell
ad
nomura
kabashima
topic
immunomodul
affect
cell
block
tcrmediat
cell
activ
may
therefor
role
treatment
ad
nomura
kabashima
furthermor
macrophag
central
pathogenesi
autoimmun
diseas
includ
ra
ad
kasrai
werfel
kinn
brauer
stuhlmul
palombokinn
burmest
abund
activ
macrophag
inflam
synovi
membran
significantli
correl
sever
ra
kinn
et
al
mulherin
fitzgerald
bresnihan
order
clinic
effect
ra
therapi
reduc
number
synovi
sublin
macrophag
bresnihan
et
al
major
macrophagerel
target
ra
ad
includ
mcsf
li
hsu
mountz
mcsfdepend
cell
known
essenti
collageninduc
arthriti
cia
develop
campbel
rich
bischof
hamilton
find
colonna
facchetti
genua
rutella
correal
danes
kasrai
werfel
kuai
et
al
suggest
target
macrophag
activ
includ
cell
activ
anoth
promis
strategi
treat
ra
ad
structur
tcr
member
mirr
famili
antigenbind
subunit
respect
bound
electrostat
intramembran
ppi
three
signal
homoand
heterodim
fig
short
synthet
peptid
capabl
inhibit
tcrmediat
cell
activ
ligandindepend
manner
known
sinc
manolio
et
al
tcrtarget
inhibitori
activ
first
report
synthet
peptid
correspond
sequenc
transmembran
domain
socal
core
peptid
cp
tcr
complex
domain
known
interact
transmembran
domain
call
et
al
manolio
bonifacino
klausner
later
cp
shown
reduc
inflamm
inhibit
progress
experiment
arthriti
kurosaka
ali
et
al
patient
ad
psoriasi
lichen
planu
daili
topic
applic
peptid
three
consecut
day
demonstr
inhibit
inflamm
amelior
diseas
equal
well
betamethason
gollner
muller
alt
knop
enk
interestingli
similar
ligandindepend
tcr
inhibitori
activ
later
report
hiv
fusion
peptid
fp
found
n
terminu
hiv
envelop
glycoprotein
bloch
et
al
quintana
gerber
kent
cohen
shai
pattern
inhibit
tcrmediat
cell
activ
exhibit
tcr
cp
hiv
fp
intriguingli
similar
peptid
inhibit
antigenbut
cell
activ
wang
djordjev
kurosaka
schibeci
lee
williamson
et
al
similar
cp
hiv
fp
shown
reduc
inflamm
amelior
cellmedi
autoimmun
arthriti
anim
model
howev
despit
extens
studi
amon
et
al
bloch
et
al
collier
bolt
manolio
kurosaka
bolt
ali
manolio
manolio
et
al
quintana
et
al
wang
djordjev
bender
manolio
mode
action
clinic
relev
peptid
enigmat
school
model
first
introduc
appli
field
sigalov
sigalov
sigalov
accord
model
sigalov
sigalov
sigalov
sigalov
cp
hiv
compet
chain
bind
disrupt
correspond
intramembran
ppi
result
disconnectionpredissoci
affect
signal
subunit
remain
receptor
complex
upon
stimul
multival
antigen
lead
inhibit
antigenbut
antibodymedi
tcr
trigger
cell
activ
importantli
tcr
assembl
cell
surfac
express
affect
treatment
cp
kurosaka
bolt
et
al
find
well
coloc
tcr
cp
tcr
membran
rest
cell
wang
djordjev
bender
et
al
directli
prove
hypothesi
pre
rather
full
dissoci
state
unstimul
tcr
complex
presenc
cp
wherea
upon
stimul
affect
signal
subunit
becom
physic
disconnect
remain
receptor
complex
note
propos
school
mechan
mechan
consist
experiment
clinic
data
report
date
transmembran
peptid
tcr
mirr
well
lipid
andor
sugar
conjug
peptid
ali
amon
bender
manolio
ali
de
planqu
huynh
manolio
separov
amon
et
al
amon
et
al
bender
ali
amon
diefenbach
manolio
collier
et
al
gerber
quintana
bloch
cohen
shai
gollner
et
al
huynh
ffrench
boadl
manolio
kurosaka
bolt
et
al
manolio
huynh
collier
sigalov
sigalov
wang
djordjev
bender
et
al
wang
djordjev
kurosaka
et
al
later
use
school
model
compar
primari
sequenc
analysi
proven
predict
immunomodulatori
sequenc
viral
fusion
protein
region
allow
suggest
specif
molecular
mechan
inhibit
tcrmediat
cell
activ
cp
hiv
fp
sigalov
sigalov
sigalov
also
predict
similar
immunomodulatori
activ
viral
fp
sarscov
fp
sigalov
recent
studi
shen
sigalov
provid
compel
experiment
vivo
evid
support
hypothesi
demonstr
synthet
amino
acidlong
peptidederiv
sar
cov
fp
predict
use
school
model
disrupt
intramembran
ppi
tcr
complex
abl
reduc
inflamm
mice
cia
protect
mice
bone
cartilag
damag
shen
sigalov
formul
peptid
selfassembl
macrophagetarget
lipopeptid
nanoparticl
mimic
nativ
human
hdl
significantli
increas
peptid
dosag
efficaci
shen
sigalov
collect
find
confirm
viral
immun
evas
strategi
evolv
hostviru
coevolut
transfer
therapeut
strategi
requir
similar
function
eg
treatment
autoimmun
diseas
express
macrophag
promis
target
develop
new
ration
therapi
autoimmun
diseas
includ
ra
kuai
et
al
addit
target
deliveri
antirheumat
drug
macrophag
anoth
highli
desir
strategi
treatment
ra
would
strike
cell
mediat
amplifi
perman
tissu
destruct
also
spare
cell
affect
joint
damag
garrood
pitzali
kinn
stuhlmul
burmest
recent
demonstr
inhibitori
nonapeptid
design
use
school
model
capabl
inhibit
macrophag
activ
ligandindepend
manner
suppress
releas
proinflammatori
cytokin
mcsf
decreas
inflamm
protect
bone
cartilag
destruct
experiment
arthriti
shen
sigalov
administr
reduc
plasma
level
mcsf
shen
sigalov
interestingli
peptid
sequenc
helic
major
hdl
protein
apolipoprotein
ai
abl
perform
three
function
assist
selfassembl
target
particl
macrophag
block
signal
shen
sigalov
similar
cancer
studi
sigalov
formul
alon
part
peptid
hdl
significantli
increas
therapeut
efficaci
coloc
macrophag
membran
observ
use
confoc
microscopi
indic
selfinsert
cell
membran
disrupt
intramembran
ppi
signal
partner
confirm
school
mechan
action
peptid
shen
sigalov
collect
find
suggest
inhibitori
school
sequenc
may
promis
altern
treatment
ra
possibl
autoimmun
diseas
septic
shock
complex
clinic
syndrom
result
system
respons
infect
character
overwhelm
product
proinflammatori
cytokin
lead
tissu
damag
also
hemodynam
chang
multipl
organ
failur
ultim
death
cohen
despit
use
potent
antibiot
advanc
resuscit
equip
cost
billion
annual
sepsi
still
kill
american
year
mortal
rate
patient
septic
shock
nearli
martin
mannino
eaton
moss
approv
sepsi
drug
xigri
eli
lilli
compani
withdrawn
market
current
approv
drug
avail
addit
drug
candid
fail
latestag
clinic
trial
togeth
highlight
urgent
unmet
medic
need
new
sepsi
treatment
macrophag
known
secret
high
level
septic
mice
ayala
chaudri
patient
sepsi
mcsf
overproduc
oren
duman
abacioglu
ozkan
irken
furthermor
elev
level
along
proinflammatori
cytokin
close
link
poor
patient
outcom
gogo
drosou
bassari
skout
importantli
patient
sepsi
express
macrophag
markedli
increas
gibot
van
bremen
et
al
initi
find
establish
amplifi
system
inflammatori
respons
syndrom
associ
sepsi
bouchon
dietrich
colonna
bouchon
et
al
blockad
septic
mice
lower
express
level
increas
surviv
control
anim
treat
anim
bouchon
et
al
gibot
et
al
wang
et
al
taken
togeth
suggest
macrophag
activ
promis
therapeut
target
syndrom
howev
discuss
earlier
develop
convent
inhibitor
attempt
block
bind
ligand
bouchon
et
al
gibot
et
al
wang
et
al
significantli
complic
unknown
natur
ligand
henc
increas
risk
failur
approach
clinic
develop
context
inhibitori
school
peptid
sequenc
employ
ligandindepend
mechan
receptor
inhibit
repres
promis
altern
convent
approach
ligandindepend
blockad
signal
pathway
mice
experiment
lipopolysaccharid
lp
induc
septic
shock
use
inhibitori
school
peptid
shown
substanti
suppress
proinflammatori
cytokin
product
prolong
surviv
septic
mice
sigalov
target
deliveri
macrophag
use
selfassembl
lipopeptid
complex
significantli
increas
peptid
halflif
therapeut
efficaci
sigalov
data
strongli
support
hypothesi
ligandindepend
modul
function
use
small
synthet
peptid
might
suitabl
treatment
sepsi
damag
integr
vessel
trigger
platelet
adhes
aggreg
result
format
thrombu
prevent
blood
loss
site
injuri
lead
occlus
irrevers
tissu
damag
infarct
diseas
vessel
lesli
nieswandt
et
al
despit
intens
research
recent
advanc
antithrombot
drug
discoveri
develop
angiolillo
bhatt
gurbel
jen
uncontrol
hemorrhag
still
remain
common
side
effect
associ
antithrombot
drug
current
use
billion
market
engag
cluster
gpvi
major
collagen
receptor
platelet
play
crucial
role
platelet
adhes
aggreg
activ
induc
collagen
jung
moroi
select
inhibit
gpvi
believ
inhibit
thrombosi
without
affect
hemostat
plug
format
thu
provid
new
therapeut
strategi
fight
plateletmedi
diseas
li
et
al
lockyer
et
al
thu
contrast
current
drug
gpvispecif
inhibitor
may
repres
ideal
class
clinic
suitabl
antithrombot
despit
intens
studi
farndal
gawaz
gibbin
okuma
farndal
barn
watson
moroi
jung
molecular
mechan
underli
gpvi
trigger
platelet
activ
known
recent
school
model
introduc
appli
gpvi
trigger
transmembran
signal
transduct
sigalov
sigalov
sigalov
sigalov
sigalov
sigalov
result
develop
novel
concept
platelet
inhibit
invent
new
platelet
inhibitor
employ
ligandindepend
school
mechan
gpvi
inhibit
sigalov
sigalov
sigalov
structur
gpvi
member
mirr
famili
signal
signal
partner
chain
moroi
jung
uncov
molecular
mechan
collagenstimul
trigger
gpvimedi
signal
cascad
school
model
reveal
intramembran
ppi
novel
therapeut
target
prevent
treatment
plateletmedi
thrombot
event
sigalov
sigalov
sigalov
sigalov
sigalov
specif
blockad
disrupt
ppi
caus
physic
function
disconnect
gpvi
subunit
experiment
data
obtain
use
gpvispecif
inhibitori
school
peptid
sigalov
sigalov
sigalov
provid
support
novel
concept
platelet
inhibit
demonstr
depend
donor
incub
whole
blood
sampl
prior
addit
collagen
convulxin
ngml
lead
reduct
percentag
pselectinposit
platelet
express
platelet
activ
marker
pselectin
effect
specif
platelet
activ
via
adp
affect
peptid
collect
find
suggest
target
intramembran
ppi
use
school
technolog
open
excit
new
avenu
innov
antithrombot
drug
discoveri
develop
patholog
retin
neovascular
rnv
caus
angiogenesisrel
vision
impair
retinopathi
prematur
rop
diabet
retinopathi
dr
retin
vein
occlus
rvo
common
caus
vision
loss
blind
age
group
jo
kim
laouri
chen
looman
gallagh
mutlu
sarici
prematur
infant
normal
retin
vascular
develop
interrupt
result
retin
ischemia
invas
vitreou
abnorm
neovessel
addit
vitreoretin
neovascular
promot
traction
retin
detach
lead
blind
alshabrawey
et
al
unit
state
prematur
infant
affect
rop
annual
million
adult
year
dr
bashinski
hartnett
complic
convent
therapeut
option
includ
laser
ablat
corneal
edema
anterior
chamber
reaction
intraocular
hemorrhag
cataract
format
intraocular
pressur
chang
mutlu
sarici
antivegf
therapi
damag
healthi
vessel
potenti
side
effect
neuron
rapid
vascular
regrowth
upon
interrupt
vegf
blockad
limit
effect
patient
maharaj
et
al
mancuso
et
al
pieramici
rabena
verheul
pinedo
highlight
unmet
need
new
target
therapi
better
address
pathogenesi
neovascular
retin
diseas
improv
treatment
addit
drug
deliveri
retina
via
system
administr
ideal
still
challeng
due
bloodretin
barrier
brb
gaudana
ananthula
parenki
mitra
retin
microglia
bloodderiv
macrophag
bdm
regul
angiogenesi
critic
involv
pathogenesi
rnv
diseas
checchin
sennlaub
levavasseur
leduc
chemtob
espinosaheidmann
et
al
kubota
et
al
rop
retina
infiltr
activ
leukocyt
macrophag
davi
eubank
power
retin
microglia
becom
activ
respons
retin
patholog
penfold
madigan
gilli
provi
infiltr
activ
bdm
may
provid
major
contribut
retin
degener
caicedo
espinosaheidmann
pina
hernandez
cousin
mice
oxygenreduc
retinopathi
oir
macrophag
promot
develop
patholog
rnv
gao
et
al
macrophag
induc
angiogenesi
secret
multipl
proangiogen
factor
includ
vegf
liu
et
al
niu
azfer
zhelyabovska
fatma
kolattukudi
proinflammatori
cytokin
nagai
et
al
inhibit
suppress
rnv
kim
byeon
hong
han
jeong
yoshida
yoshida
ishibashi
elner
elner
mcsf
act
angiogen
switch
lin
et
al
involv
differenti
tissu
macrophag
microglia
postnat
develop
cecchini
et
al
contrast
vegf
blockad
interrupt
mcsf
inhibit
promot
rapid
vascular
regrowth
kubota
et
al
oir
mice
mcsf
requir
patholog
rnv
recoveri
normal
vasculatur
kubota
et
al
retina
diabet
rat
vitreou
patient
prolif
dr
mcsf
level
significantli
higher
compar
control
subject
liu
xu
jiang
da
yoshida
et
al
suggest
target
mcsf
either
directli
via
specif
inflammatori
signal
pathway
highli
promis
strategi
treat
ocular
neovascular
diseas
includ
rop
upregul
varieti
inflammatori
condit
pelham
agraw
upon
activ
enhanc
product
multipl
cytokin
growth
factor
includ
mcsf
dower
et
al
lagler
et
al
schenk
et
al
shen
sigalov
sigalov
howev
despit
recent
identif
novel
hypox
marker
vivo
vitro
bosco
et
al
role
rnv
diseas
includ
rop
remain
unclear
recent
found
highli
overexpress
retina
oir
mice
compar
control
modesto
roja
zu
shen
ruth
b
caldwel
alexand
b
sigalov
unpublish
data
blockad
use
inhibitori
school
peptid
sequenc
substanti
suppress
retin
protein
level
mcsf
suggest
mcsfdepend
inhibitori
effect
angiogenesi
significantli
reduc
area
vitreoretin
neovascular
modesto
roja
zu
shen
ruth
b
caldwel
alexand
b
sigalov
unpublish
data
collect
promis
data
suggest
target
intramembran
ppi
receptor
complex
use
school
peptid
inhibitor
repres
novel
strategi
treat
rnv
diseas
includ
rop
grow
interest
therapeut
target
specif
ppi
involv
receptormedi
transmembran
signal
transduct
improv
understand
molecular
mechan
underli
process
significantli
contribut
develop
novel
pharmacolog
approach
varieti
diseas
exampl
school
platform
uncov
molecular
mechan
transmembran
signal
mediat
unrel
function
divers
surfac
receptor
express
variou
cell
reveal
specif
ppi
involv
receptor
trigger
key
point
therapeut
control
importantli
school
platform
suggest
within
sr
mirr
famili
similar
structur
architectur
receptor
dictat
similar
mechan
receptor
trigger
turn
suggest
similar
therapeut
target
seemingli
unrel
diseas
make
possibl
develop
global
pharmacolog
approach
well
transfer
clinic
knowledg
experi
therapeut
strategi
diseas
success
applic
school
strategi
target
vivo
intramembran
ppi
involv
trigger
unrel
receptor
tcr
gpvi
express
cell
macrophag
platelet
respect
provid
compel
evid
support
hypothesi
result
discoveri
new
drug
candid
varieti
diseas
includ
cancer
sepsi
ra
ad
retinopathi
school
platform
significantli
improv
understand
immunomodulatori
activ
mani
human
virus
appear
differ
virus
use
fusogen
peptid
fuse
membran
target
host
cell
also
disarm
immun
system
use
school
mechan
receptor
inhibit
escap
host
immun
respons
give
interest
exampl
advanc
mechanist
understand
fundament
natur
process
interact
elucid
billion
year
old
strategi
natur
use
combinatori
control
optim
differ
scale
evolut
organism
function
work
partial
support
defens
advanc
research
project
agenc
darpa
us
armi
research
offic
contract
nation
cancer
institut
nation
institut
health
grant
number
nation
institut
arthriti
musculoskelet
skin
diseas
nation
institut
health
grant
number
addit
fund
come
signablok
inc
author
thank
dr
zu
shen
critic
read
manuscript
excel
help
figur
